These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33380563)

  • 21. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
    Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
    Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregabalin: new drug. Very similar to gabapentin.
    Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids.
    Tang H; Lu J; Duan Y; Li D
    Mediators Inflamm; 2023; 2023():4893436. PubMed ID: 37152369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of mirogabalin and pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study.
    Nakajima R; Ooba N; Kamei M; Hashiba H; Miyazaki C
    Expert Opin Drug Saf; 2023; 22(9):841-848. PubMed ID: 36945742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abuse potential of mirogabalin in recreational polydrug users.
    Mendell J; Levy-Cooperman N; Sellers E; Vince B; Kelsh D; Lee J; Warren V; Zahir H
    Ther Adv Drug Saf; 2019; 10():2042098619836032. PubMed ID: 31057786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirogabalin: First Global Approval.
    Deeks ED
    Drugs; 2019 Mar; 79(4):463-468. PubMed ID: 30778848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin.
    Yamanaka T; Takeshita K; Mochizuki T; Inoue H; Akiyama T
    Spine Surg Relat Res; 2023 Mar; 7(2):136-141. PubMed ID: 37041868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Anti-Allodynic Gabapentinoids: Myths, Paradoxes, and Acute Effects.
    Alles SRA; Smith PA
    Neuroscientist; 2017 Feb; 23(1):40-55. PubMed ID: 27118808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study.
    Akazawa T; Inoue G; Tanaka M; Umehara T; Nagai T; Oshita Y; Imura T; Miyagi M; Saito W; Sako K; Nomura S; Hiyama A; Katoh H; Sakai D; Sato M; Yoshida A; Iinuma M; Niki H; Takaso M; Watanabe M
    Global Spine J; 2023 Jun; 13(5):1319-1324. PubMed ID: 34325544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery.
    Liu B; Liu R; Wang L
    Medicine (Baltimore); 2017 Sep; 96(37):e8031. PubMed ID: 28906391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of Pregabalin or Gabapentin in Neuropathic Rats.
    Pineda-Farias JB; Caram-Salas NL; Salinas-Abarca AB; Ocampo J; Granados-Soto V
    Drug Dev Res; 2017 Dec; 78(8):371-380. PubMed ID: 28868795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregabalin as a Pain Therapeutic: Beyond Calcium Channels.
    Alles SRA; Cain SM; Snutch TP
    Front Cell Neurosci; 2020; 14():83. PubMed ID: 32351366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anxiolytic effects of the novel α
    Murasawa H; Kobayashi H; Saeki K; Kitano Y
    Psychopharmacology (Berl); 2020 Jan; 237(1):189-197. PubMed ID: 31515584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (L)-Phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats.
    Lynch JJ; Honore P; Anderson DJ; Bunnelle WH; Mortell KH; Zhong C; Wade CL; Zhu CZ; Xu H; Marsh KC; Lee CH; Jarvis MF; Gopalakrishnan M
    Pain; 2006 Nov; 125(1-2):136-42. PubMed ID: 16781071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
    Brown K; Mendell J; Ohwada S; Hsu C; He L; Warren V; Dishy V; Zahir H
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00418. PubMed ID: 30151212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of calcium channel alpha-2-delta-1 subunit in dorsal horn contributes to spinal cord injury-induced tactile allodynia.
    Kusuyama K; Tachibana T; Yamanaka H; Okubo M; Yoshiya S; Noguchi K
    Spine J; 2018 Jun; 18(6):1062-1069. PubMed ID: 29355786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights.
    Kremer M; Salvat E; Muller A; Yalcin I; Barrot M
    Neuroscience; 2016 Dec; 338():183-206. PubMed ID: 27401055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.
    Arnold LM; Whitaker S; Hsu C; Jacobs D; Merante D
    Curr Med Res Opin; 2019 Oct; 35(10):1825-1835. PubMed ID: 31284771
    [No Abstract]   [Full Text] [Related]  

  • 39. Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.
    McAnally H; Bonnet U; Kaye AD
    Pain Ther; 2020 Dec; 9(2):441-452. PubMed ID: 32737803
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.